IBRULIEVA 140 MG (Ibrutinib Capsules 140 mg) is a targeted anticancer medicine used in the treatment of certain blood cancers and lymphatic system cancers. It contains Ibrutinib, a highly effective Bruton's Tyrosine Kinase (BTK) inhibitor that helps slow down and control the growth of abnormal cancer cells in the body. This medicine is commonly prescribed by oncologists and hematology specialists for the management of chronic blood-related malignancies and advanced lymphoma conditions.

Ibrutinib works by targeting specific proteins responsible for the growth and survival of cancer cells. By blocking BTK activity, the medicine interferes with cancer cell signaling pathways and helps reduce the spread of abnormal B-cells. Due to its targeted mechanism of action, IBRULIEVA 140 MG has become an important medicine in modern hematology-oncology treatment protocols.

This targeted therapy capsule is widely used in the treatment of:

     • Chronic Lymphocytic Leukemia (CLL)

     • Small Lymphocytic Lymphoma (SLL)

     • Mantle Cell Lymphoma (MCL)

     • Waldenström Macroglobulinemia (WM)

     • Marginal Zone Lymphoma (MZL)

     • Chronic Graft Versus Host Disease (cGVHD)

Doctors may prescribe IBRULIEVA alone or in combination with other oncology medicines depending on the patient’s medical condition, stage of cancer, treatment history, and response to therapy.

IBRULIEVA 140 MG is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. The medicine is intended strictly for medical use and should only be taken under the supervision of qualified healthcare professionals.

Blood cancers and lymphatic malignancies can affect the immune system, bone marrow, lymph nodes, and overall health. Targeted cancer therapies like Ibrutinib help improve disease management by specifically targeting cancer-related pathways without affecting healthy cells as extensively as traditional chemotherapy.

Patients receiving IBRULIEVA 140 MG may require regular blood tests, medical monitoring, and health assessments during treatment to help manage side effects and improve treatment outcomes. Doctors carefully determine dosage and treatment duration based on the patient’s overall condition and treatment goals.

Due to its effectiveness in targeted cancer treatment and hematology care, IBRULIEVA 140 MG is widely used in hospitals, oncology centers, hematology clinics, and advanced cancer treatment programs.

IBRULIEVA 140 MG (Ibrutinib Capsules 140 mg) is mainly used for the treatment and management of various blood cancers and lymphatic system disorders.

Common Uses of IBRULIEVA 140 MG

1. Chronic Lymphocytic Leukemia (CLL)

IBRULIEVA is widely used in the treatment of chronic lymphocytic leukemia, a type of blood cancer affecting white blood cells.

2. Small Lymphocytic Lymphoma (SLL)

Doctors may prescribe Ibrutinib Capsules for patients with small lymphocytic lymphoma, which affects the lymphatic system.

3. Mantle Cell Lymphoma (MCL)

The medicine is commonly used in patients with mantle cell lymphoma who require advanced targeted cancer therapy.

4. Waldenström Macroglobulinemia (WM)

IBRULIEVA helps manage Waldenström macroglobulinemia, a rare type of non-Hodgkin lymphoma affecting abnormal white blood cells.

5. Marginal Zone Lymphoma (MZL)

This targeted therapy medicine may also be used in patients with marginal zone lymphoma after previous treatment failure.

6. Chronic Graft Versus Host Disease (cGVHD)

Doctors may prescribe Ibrutinib for chronic graft versus host disease in certain patients requiring immune-related therapy support.

7. Advanced Hematology Treatment

IBRULIEVA is widely included in advanced hematology-oncology treatment protocols for long-term disease management.

---

How IBRULIEVA 140 MG Works

Ibrutinib belongs to a class of medicines known as Bruton’s Tyrosine Kinase (BTK) inhibitors.

IBRULIEVA works by:

     • Blocking BTK protein activity

     • Interfering with cancer cell signaling

     • Reducing abnormal B-cell growth

     • Slowing cancer progression

     • Helping cancer cells die naturally

This targeted mechanism helps control blood cancer growth more effectively.

Like other anticancer medicines, IBRULIEVA 140 MG may cause side effects in some patients. Side effects may vary depending on the patient’s health condition, treatment duration, and response to therapy.

Common Side Effects

1. Diarrhea

Digestive discomfort or loose stools may occur during treatment.

2. Fatigue or Weakness

Patients may experience tiredness, weakness, or reduced energy levels.

3. Muscle or Joint Pain

Some individuals may develop body aches, muscle pain, or joint discomfort.

4. Nausea

Mild nausea or stomach discomfort may occur during therapy.

5. Fever

Patients may occasionally experience fever or infection-related symptoms.

6. Bruising or Bleeding

IBRULIEVA may increase the risk of bruising or minor bleeding in certain patients.

7. Rash

Skin rash or irritation may develop during treatment.

8. Swelling

Swelling in hands, feet, or legs may occur in some individuals.

9. Reduced Blood Cell Counts

The medicine may lower blood cell levels and increase infection risk.

---

Serious Side Effects

Some serious side effects may require immediate medical attention.

Seek Medical Help If You Experience:

     • Severe bleeding

     • Chest pain

     • Difficulty breathing

     • Irregular heartbeat

     • Severe infection symptoms

     • Severe allergic reactions

     • Black stools or blood in urine

     • Sudden weakness or dizziness

Patients should immediately contact their healthcare provider if serious symptoms occur during treatment.

The dosage of IBRULIEVA 140 MG (Ibrutinib Capsules 140 mg) should always be determined by a qualified healthcare professional based on the patient’s medical condition and treatment requirements.

Factors Affecting Dosage

1. Type of Cancer

Dosage depends on the specific blood cancer or lymphoma being treated.

2. Medical Condition

The patient’s overall health and treatment history influence dosage planning.

3. Response to Therapy

Doctors may adjust dosage depending on treatment response and side effects.

4. Liver Function

Patients with liver-related conditions may require dosage adjustments.

5. Combination Treatment

Dosage may vary when Ibrutinib is used along with other oncology medicines.

---

Important Dosage Instructions

     • Take the capsule exactly as prescribed

     • Swallow the capsule whole with water

     • Do not crush or chew the capsule

     • Take the medicine at the same time daily

     • Do not stop treatment without medical advice

     • Regular blood monitoring may be necessary

Patients should follow their oncologist’s treatment schedule carefully.

---

Precautions Before Using IBRULIEVA 140 MG

Before starting treatment, patients should inform their doctor if they have:

     • Heart disease

     • Liver disorders

     • Bleeding problems

     • High blood pressure

     • Active infections

     • Previous cancer treatment complications

Patients should also discuss all ongoing medicines and supplements to avoid possible drug interactions.

Pregnant or breastfeeding women should only use this medicine if recommended by a healthcare professional.

---

Storage Instructions

     • Store in a cool and dry place

     • Protect from direct sunlight and moisture

     • Keep out of reach of children

     • Store at recommended room temperature

---

Why Choose IBRULIEVA 140 MG?

     • Advanced targeted cancer therapy

     • Trusted hematology-oncology medicine

     • Effective BTK inhibitor formulation

     • Reliable blood cancer treatment support

     • Manufactured under strict pharmaceutical standards

     • Suitable for modern oncology treatment protocols

---

Frequently Asked Questions (FAQs)

What is IBRULIEVA 140 MG used for?

It is mainly used for the treatment of blood cancers such as chronic lymphocytic leukemia, mantle cell lymphoma, and related conditions.

What is Ibrutinib?

Ibrutinib is a targeted anticancer medicine known as a BTK inhibitor used in hematology-oncology treatment.

Is IBRULIEVA a chemotherapy medicine?

It is considered a targeted therapy medicine rather than traditional chemotherapy.

Can IBRULIEVA cause bleeding?

Yes, some patients may experience bruising or bleeding-related side effects during treatment.

Is regular monitoring necessary during therapy?

Yes, doctors usually recommend blood tests and regular medical monitoring during treatment.

Can patients stop treatment suddenly?

No, patients should never stop treatment without consulting their healthcare provider.

Should IBRULIEVA be used under medical supervision?

Yes, this medicine should always be used under the supervision of qualified healthcare professionals.

Can IBRULIEVA help control cancer progression?

Yes, the medicine helps slow cancer growth and supports long-term disease management in eligible patients.